 Emerg Med 1998;15:252-253) 
Eighteen per cent of patients (6/34) had a biphasic reaction. The initial presenting features were similar to those of the uniphasic group. None of these cases involved repeated exposure to the causal agent. The interval until development of the second stage of the biphasic response ranged from 4.50 to 29.50 hours. The symptoms exhibited in the second stage were similar to those of the initial presentation (table 3) .
Patients with a uniphasic reaction required from 0.3 to 1 mg adrenaline (mean 0.6 mg) to treat symptoms. Patients with a biphasic reaction required 0.5 to 2.0 mg adrenaline to control symptoms at initial presentation (mean 1.2 mg). This difference was statistically significant (p = 0.03, 95% confidence interval 0 to 1 mg). The dose of adrenaline required to treat second stage features of biphasic reactions varied between 0.4 to 1.0 mg (mean 0.5 mg).
Discussion
The potential for the return of severe symptoms in someone who appears to have been successfully treated for an acute anaphylactic reaction is often underestimated. Biphasic reactions occurred in 18% of cases in this study with the second phase response developing more then 29 hours after the first in one patient (see table 3, patient 3). This incidence is similar to that previously reported by Sampson and Mendelson (23%)8 but is considerably greater than that reported by Douglas et al (5% for inpatients and 7% for outpatients ).7 Our study confirms that there were no presenting clinical features that predicted a biphasic response. It has been suggested that those who ingest the antigen are at higher risk of developing a biphasic response.6 This would only have identified half of our cases and we do not thus consider it a reliable indicator.
Our study identified that those who went on to develop a biphasic response required significantly more adrenaline to treat their initial reaction, although the number of patients in the study was small. We are not aware of previous similar reports in the literature. This would suggest that patients who require higher doses of adrenaline to treat anaphylaxis are at greater risk of a subsequent biphasic reaction. We are planning a prospective study with a larger group of patients to test this hypothesis.
All patients requiring adrenaline to control an anaphylactic reaction should be admitted for observation for at least 24 hours. Patients should only be discharged after being educated in the recognition and treatment of anaphylaxis.
